科兴制药携手澳斯康生物进军欧美生物类似药市场

Core Viewpoint - Recently, Kexing Pharmaceutical and Auscan Biopharmaceutical Co., Ltd. have established a strategic partnership to jointly develop the KXBS001 biosimilar, marking their entry into the European and American biosimilar markets [1] Group 1: Strategic Partnership - Kexing Pharmaceutical has formed a strategic collaboration with Auscan Biopharmaceutical to develop biosimilars [1] - The partnership aims to leverage both companies' strengths to accelerate the research and development process of the KXBS001 biosimilar [1] Group 2: Market Opportunities - The European Medicines Agency (EMA) has recently announced a draft plan to simplify the review process for biosimilars, potentially providing a "fast track" for domestic pharmaceutical companies to enter the EU market [1] - According to an IQVIA report, the EU accounts for approximately 40% of the global biosimilar market value [1] Group 3: Company Strategies - Kexing Pharmaceutical adheres to an "innovation + internationalization" strategy and has developed a comprehensive antibody technology platform with capabilities across various therapeutic areas, including antiviral, oncology, and autoimmune diseases [1] - Auscan Biopharmaceutical's chairman highlighted Kexing's rapid progress in internationalization and expressed confidence in leveraging cutting-edge technology to enhance the collaboration [1] - Kexing's chairman noted that Auscan's team possesses extensive experience in CMC development and commercialization in the large molecule field, indicating a strong foundation for future collaboration [1]